An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily in Subjects With Cancer Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China
-
Chengdu, China
-
Fu Zhou, China
-
Guangdong, China
-
Guangzhou, China
-
Hangzhou, China
-
Hefei, China
-
Nanchang, China
-
Nanning, China
-
Shanghai, China
-
Tianjin, China
-
Wuhan, China
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants receiving strong oral or transdermal (through the skin) opioid analgesics with inadequate control of moderate to severe (very serious, life threatening) cancer pain or who presented with cancer pain and will be eligible to move to Step 3 of the WHO analgesic ladder when receiving weak opioids
- Participants who require or are expected to require between 40 mg and 184 mg of oral morphine or morphine equivalents every 24 hours for the chronic management of cancer pain
- Participants who are reasonably expected to achieve a stable dose of opioid study medication during the study
- Participants who are not expected to start a course of chemotherapy, radiotherapy, targeted cancer therapy, hormone therapy or diphosphates therapy after enrolment into the study. If participants are receiving long-term treatment including hormone therapy, target cancer therapy and diphosphate, the treatment should be kept stable as much as possible from 2 weeks before randomization and up to the completion of the study, encompassing the titration and maintenance phases
- Female participants who are premenarchal, postmenopausal, or surgically sterile, abstinent or if sexually active, they must use a medically acceptable method of contraception and must be willing to continue to use the same method of contraception throughout the study
Exclusion Criteria:
- Participants with neuropathic pain or pain of unknown origin, or acute pain - Participants having pain only on movements
- Participants requiring other opioid analgesics (apart from morphine hydrochloride (HCl), in immediate release formulation, allowed as rescue medication for breakthrough pain)
- Participants with a recent history (within the previous 6 months) or current history of drug abuse or alcohol abuse
- Women of childbearing potential who were pregnant or lactating, seeking pregnancy or failing to use an adequate contraceptive method
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: OROS Hydromorphone hydrochloride (HCl)
OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase.
Starting dose will be based on participant's previous daily opioid dose.
|
Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase.
Starting dose will be based on participant's previous daily opioid dose.
Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
|
|
Active Comparator: Oxycodone HCl Controlled release (CR)
Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase.
Starting dose will be based on participant's previous daily opioids dose.
|
Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase.
Starting dose will be based on participant's previous daily opioids dose.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29
Time Frame: Baseline and Day 29
|
The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines.
Change in worst pain in the past 24 hours in BPI score was reported.
The total score ranges from 0 to 10, wherein 0 indicates no pain and 10 indicates pain as bad as participants could imagine.
|
Baseline and Day 29
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Pain at Its Least, in the Past 24 Hours Assessed by BPI Short Form Questionnaire Score at Day 29
Time Frame: Baseline and Day 29
|
The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines.
Change in pain at its least, in the past 24 hours in BPI score was reported.
The total score ranges from 0 to 10, wherein 0 indicates no pain and 10 indicates pain as bad as participants could imagine.
|
Baseline and Day 29
|
|
Change From Baseline in Average Pain, in the Past 24 Hours Assessed by BPI Short Form Questionnaire Score at Day 29
Time Frame: Baseline and Day 29
|
The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines.
Change in average pain in the past 24 hours, in BPI score was reported.
The score ranges from 0 to 10 wherein, 0 indicates no pain and 10 indicates pain as bad as participants could imagine.
|
Baseline and Day 29
|
|
Change From Baseline in Pain Right Now Assessed by BPI Short Form Questionnaire Score at Day 29
Time Frame: Baseline and Day 29
|
The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines.
Change in Pain Right now in BPI was reported.
The score ranges from 0=no pain to 10=pain as bad as participants could imagine.
|
Baseline and Day 29
|
|
Change From Baseline in Pain Relief, in the Past 24 Hour Recorded Assessed by BPI Short Form Questionnaire at Day 29
Time Frame: Baseline and Day 29
|
The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines.
BPI comprises of total 9 items in total, and the 8th item consisting of 7 sub-items is a question asking the degree of disturbance due to pain.
The score ranges from 0% to 100%, wherein 0% indicates no relief and 100% indicates complete relief.
|
Baseline and Day 29
|
|
Breakthrough Pain Medication (Rescue Medication) Doses Taken
Time Frame: Baseline up to Day 29
|
Any breakthrough pain medication taken during the overall study was reported.
Morphine hydrochloride was used as a rescue medication in case of breakthrough pain.
|
Baseline up to Day 29
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Johnson & Johnson Pharmaceutical Research and Development Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR017437
- 42801PAI3009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.